|
Mutation Information
|
Mutation Site
|
M204V |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Combined Mutation
|
rt.M204V+rt.L180M;rt.M204V+rt.T184S;rt.M204V+rt.L180M+rt.V173L;rt.M204V+rt.T184L+rt.L180M;rt.M250L+rt.M204V+rt.L180M;rt.M204V+rt.S202G+rt.L180M |
|
Relevant Drug
|
lamivudine (LAM) |
|
Country
|
China |
Literature Information
|
PubMed PMID
|
28300730
|
|
Disease
|
Chronic hepatitis B
|
|
Published Year
|
2017 |
|
Journal
|
Antiviral therapy |
|
Title
|
The enrichment of HBV immune-escape mutations during nucleoside/nucleotide analogue therapy. |
|
Author
|
Shan M,Shen Z,Sun H,Zheng J,Zhang M |
|
Evidence
|
RESULTS: A total of 97 patients in the NA treatment group had resistance mutations, with rtM204I/V/S being the most common substitution (78 of 97), while no resistance mutations were detected in the treatment-naive group.
|
|
|
HBV Mutation Detail Information